Introduction
Veno-venous extracorporeal membrane oxygenation (VV ECMO) is used for refractory respiratory failure. Previously, we described our technique of percutaneous placement of venoarterial (VA) ECMO cannulas. 1 We now describe the percutaneous placement of a cannula for VV ECMO support, including indications, patient assessment, preparation for cannulation and the technical aspects of the procedure using a double lumen bi-caval cannula (Avalon, Maquet, Rastatt, Germany).
Indications

VV ECMO is reserved for patients with compromise of their ventilation or oxygenation
status that is refractory to optimum mechanical ventilation and medical therapy. [2] [3] [4] In VV ECMO, deoxygenated blood is drained from the venous system, and sent through an external circuit which contains a gas-permeable membrane that removes carbon dioxide and an oxygenator that oxygenates the blood. Thereafter the blood is returned to the venous system, whereas in VA ECMO the oxygenated blood is returned to the arterial system. 1 Distribution of the oxygenated blood to the patient in VV ECMO requires viability of the patient's own circulatory system and therefore VV ECMO depends on the patient having normal cardiac function to maintain adequate perfusion. 4 Thus, the primary indication of VV ECMO is severe acute ventilatory and/or oxygenation failure that the patient is unlikely to survive with conventional mechanical ventilation but is potentially reversible and is not associated with cardiac failure. [2] [3] [4] Common conditions of reversible respiratory failure for which VV ECMO is a potential treatment option include adult respiratory distress syndrome (ARDS) due to aspiration, viral/bacterial/atypical pneumonia, barotrauma, and acute on chronic interstitial pneumonitis. 
Pre-procedural assessment
Typical candidates are hypercapnic, hypoxic and unresponsive to optimal medical management, including low-tidal volumes, bronchodilator treatment, administration of epoprostenol, paralysis, and appropriate diuresis. 2 It is important to establish the acute nature of the respiratory failure, ruling out cardiac or other non-pulmonary organ failure, and confirming a failure to improve with ventilator management. If it appears VV ECMO is clinically indicated and the patient would benefit from the therapy, the next step is to identify any patient factors that may prevent placement of the VV ECMO cannula.
The right internal jugular vein should be evaluated with ultrasound to identify intrinsic or acquired vascular pathologies including deep vein thrombosis, stenosis or previous stent placements that may preclude cannula placement. The placement of cannulas may be technically difficult in morbidly obese patients. Additional information such as coagulopathies or any contraindications to anticoagulation should be noted. Echocardiography should be performed before the procedure to rule out cardiac dysfunction or structural abnormalities such as a patent foramen ovale or tricuspid regurgitation. 5 The presence of those structural abnormalities may cause inadequate mixing of ECMO inflow and outflow. Additionally, VV ECMO placement in a 5 patient with cardiac failure of either side can result in cardiac over-distension and worsening pulmonary edema.
The protocol at our institution for patients who meet criteria for VV ECMO but who are not candidates for this system secondary to limitations of venous access, cardiac dysfunction or a structural abnormality is to place VA ECMO.
The local internal review board approved this presentation.
Traditional VV ECMO cannulation
Prior to the advent of the Avalon cannula, placement of VV ECMO support required multiple cannulation sites. The traditional VV ECMO system involved bilateral groin cannulations with one long venous cannula extending into the right atrium serving as inflow of oxygenated blood to the patient and one short venous cannula ending in the inferior vena cava (IVC) serving as outflow of the unoxygenated blood ( Figure 1A) . A second variation of the preAvalon VV ECMO system consisted of an outflow cannula in the groin ending in the IVC and a inflow cannula in the right atrium placed from the upper extremity ( Figure 1B ). These VV ECMO systems may result in ineffective oxygenation via ECMO due to the proximity of the inflow and outflow cannulas: the outflow cannula could be drawn back into the ECMO circuit without going into the patient's circulatory system. Another potential issue of these double cannulation systems was the potential for low ECMO flow related to a relatively easily collapsible IVC due to suction effect from the outflow cannula, which often observed in low intravascular volume status.
Avalon double lumen bi-caval cannula
In our practice, we use a double lumen bi-caval cannula (Avalon cannula) for VV ECMO. This Avalon cannula is a rigid straight cannula that was designed to be inserted from the 6 right internal jugular vein into the IVC. Due to the rigidity of the cannula, other upper extremity cannulation such as subclavian or left internal jugular vein access is not recommended. The
Avalon catheter has 3 ports referred to as the proximal, middle and distal ports. The distal port located at the tip of the Avalon cannula should be placed just below the atrial-IVC junction.
Once the distal port is positioned inside the proximal portion of the IVC, the proximal port of the cannula should be in the SVC. These proximal and distal ports drain unoxygenated blood from the upper and lower body, respectively. The middle port of the Avalon catheter should rest in the right atrium and ideally face towards the tricuspid valve. Oxygenated blood from ECMO circuit is delivered to this middle port. Then the oxygenated blood is circulated to the pulmonary vasculature followed by the systemic circulation by native cardiac function. 6, 7 The Avalon cannula has specially designed to minimize inflow-outflow reperfusion and shunting of oxygenated blood.
The additional advantage of the dual-lumen design of the Avalon catheter is that it does not require femoral cannulation. Femoral cannulation hinders the ability to use prone positioning, which is a common secondary intervention performed in VV ECMO patients to improve oxygenation and lung recruitment. Avoiding a femoral cannulation also allows patients to sit in bed or even ambulate while on VV ECMO support. Percutaneous placement of VV ECMO cannulas can be performed in a variety of hospital settings including an emergency room, a cardiac cauterization laboratory, an intensive care unit or an operating room; however use of fluoroscopy is strongly recommended to ensure proper positioning of the wires and the cannula. We prefer to use a percutaneous approach to place the cannula as this minimizes bleeding from the cannulation site. The procedure is preferentially performed in the intensive care unit with fluoroscopy with trained personnel, support staff and the necessary equipment being readily available. Prior to the procedure, the patient needs to be sedated adequately with an airway properly secured.
Two operators should be available to control the wires and cannulas. The patient is prepped and draped sterilely and a single dose of intravenous antibiotics is administered. We routinely prep both groins for a possible conversion to VA ECMO in case we fail to obtain right internal jugular vein access.
Percutaneous puncture of the right internal jugular vein is performed under ultrasound guidance. The puncture site should be some distance from the clavicle. Otherwise, it is difficult to obtain adequate exposure upon decannulation or if the vessel needs to be repaired. Cannulas are selected preoperatively based on manufacture pressure flow curves and the optimal flow calculated from a formula based on body surface area (BSA) x 2.2. We use this formula to provide optimal cardiac index. Usually, maximum flow is limited to 3 L/min with use of a 23Fr cannula, 4.5 L/min with a 27Fr cannula, and greater than 6.5 L/min with 31Fr Avalon cannula. Although ECMO cannulas have the ability to run above the recommended flow, doing so may cause hemolysis; thus, in general, our policy is to utilize the largest cannula feasible.
Systemic anticoagulation is required to prevent forming thrombus in the ECMO circuit.
Therefore, after the tract is dilated, a 5000 unit intravenous bolus of heparin (7500 units for BSA >2.2) is administered to prevent thrombosis prior to placement of the Avalon cannula. An inner stylet was placed in the Avalon cannula to facilitate the insertion over the guide wire along the 9 dilated tract. The tip of the inner stylet should be followed by fluoroscopy to ensure not to kink the wire by the sharp tip of the inner stylet. The inner stylet is partially withdrawn as the cannula is inserted into the SVC to avoid injury to the right atrium by the inner stylet. Fluoroscopy should be used to confirm the cannula tip terminates in the IVC ( Figure 2C , Figure 3A) . At this point a bedside echocardiography is performed to confirm the middle port of the catheter is positioned in the right atrium with outflow jetting into the tricuspid valve ( Figure   3B ). 5 The cannula can be moved manually to position the middle port of the cannula if needed.
The catheter is secured to the skin with several sutures.
The entire procedure takes about 30 minutes with minimal blood loss (less than 100cc is expected). However, it is advisable to have two units of packed red blood cells as well as All patients were placed on VV ECMO with Avalon cannula. Early on, we experienced one incidence of cannula malposition into the right ventricle, which required surgical exploration. 8 Now with our routine use of fluoroscopy for cannulation, we have not experienced 12 any additional incidences of malposition of the cannula. However, there have been 5 incidences of cannula migrations, which required reposition of the cannula under either fluoroscopy or ultrasound. 9 No patient required conversion to the VA ECMO or extra-venous cannula in addition to the Avalon cannula system.
The average length of VV ECMO was 11.5 ± 6.7 days. Thirty four patients (76%) were successfully weaned from VV ECMO and survived of ECMO. The details of 11 patients who died during VV ECMO were sepsis secondary to pre-existing infection (3), cardiac death related to implantable cardiac assist device (2), stroke (2), non-recoverable pulmonary fibrosis (2), and ischemic bowel (2) . After ECMO decannulation, 29 patients (64%) were discharged home with appropriate neurological status.
Conclusion
Current practice of VV ECMO using a dual-lumen Avalon catheter requires experienced staff and adjunct equipment including ultrasound, echocardiography and fluoroscopy.
Utilization of a standard protocol as described above will reduce complications and increase the likelihood of successful placement of VV ECMO. Figure 3B ).
